Beam Therapeutics Presents Data Highlighting Robust Manufacturing Process For BEAM-101 At EHA 2024 Hybrid Congress June 13-16, 2024
Beam Therapeutics Presents Data Highlighting Robust Manufacturing Process For BEAM-101 At EHA 2024 Hybrid Congress June 13-16, 2024
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report data highlighting the robust, closed and automated manufacturing process for BEAM-101, as deployed in the BEACON Phase 1/2 clinical trial, in a poster presentation at the European Hematology Association (EHA) Hybrid Congress, hosted virtually and in person in Madrid, Spain on June 13-16, 2024.
通过基础编辑开发精准遗传药物的生物技术公司Beam Therapeutics Inc.（纳斯达克股票代码：BEAM）今天宣布，该公司将在2024年6月13日至16日在西班牙马德里虚拟和面对面举办的欧洲血液学协会（EHA）混合大会上发布的海报发布会上报告数据，重点介绍BEACON 1/2期临床试验中部署的稳健、封闭和自动化的 BEAM-101 制造工艺。
Abstract details are listed below and available online on the EHA meeting library website.
摘要详细信息如下所列，可在EHA会议图书馆网站上在线获取。
Title: Robust autologous CD34+ HSPC manufacturing with a closed and automated process optimized for patients with sickle cell disease
Poster Session Date and Time: Friday, June 14, 2024, 6:00 p.m. CEST
Abstract: P1479
Presenting Author: Paul Kopesky, Ph.D., vice president, process development at Beam Therapeutics
标题：稳健的自体 CD34+ HSPC 制造，采用封闭的自动化流程，针对镰状细胞病患者进行了优化
海报发布会日期和时间：欧洲中部标准时间 2024 年 6 月 14 日星期五下午 6:00
摘要：P1479
主讲作者：保罗·科佩斯基博士，Beam Therapeutics工艺开发副总裁